BPC-157: what it is, how to get a prescription and what it costs

BPC-157 is a lab-made peptide of 15 amino acids based on a protein in stomach juice. Human evidence is three small uncontrolled studies with 30 people in total (Poolton 2026, PubMed 42885452). It is not FDA-approved. Since 28 October 2026, licensed 503A pharmacies can compound it under an interim HHS policy. Prescription programs start at $149 a month; see every BPC-157 price.

Below: what BPC-157 is, what the studies in people actually show, where it stands legally, how a prescription program works, which programs sell it and what to ask before you pay.

What BPC-157 is

BPC stands for Body Protection Compound. A 2026 drug-development review describes it as a "synthetic pentadecapeptide derived from a gastric protein fragment with reported cytoprotective and regenerative properties across multiple organ systems" (Mateescu 2026, PubMed 42198317). Pentadecapeptide simply means a chain of 15 amino acids.

The same review is blunt about how far the drug is from being a medicine: after three decades of preclinical work it has "no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial" (Mateescu 2026). Most of what you read about BPC-157 for tendons, ligaments, gut lining or muscle comes from preclinical studies, not from people.

The one program selling it says much the same on its own page: "Human studies are small and early" (Superpower BPC-157 page).

What the evidence shows in people

We searched PubMed on 30 October 2026. Only three studies have given BPC-157 to people and reported results, all led by the same author at private clinics in Florida:

A systematic review of these three studies, searched up to June 2026, judged all of them "to be of poor methodological quality" and concluded that "Overall certainty of evidence was rated very low due to serious risk of bias, indirectness and imprecision" (Poolton 2026, PubMed 42885452). An orthopaedic review published this week reached the same view for injuries: "human musculoskeletal evidence is limited to one small retrospective uncontrolled case series without validated outcome measures" (Tham 2026, PubMed 42937313).

An earlier sports-medicine review found 36 studies, of which 35 were preclinical, and noted: "No clinical safety data were found" (Vasireddi 2025, PubMed 40756949).

In plain terms: BPC-157 is a research compound with interesting preclinical results and almost no controlled human data. Nobody has shown in a proper trial that it speeds healing in people. For side effects and the open safety questions, see BPC-157 side effects and safety.

Is BPC-157 legal now?

In 2023 FDA placed BPC-157 in category 2, its list of bulk substances that may present significant safety risks in compounding. FDA's page still carries its assessment: compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization" (FDA category 2 page). The page now lists BPC-157 under substances whose nominations were withdrawn.

On 28 October 2026 HHS issued an interim enforcement-discretion policy, published in the Federal Register on 30 October. HHS wrote that it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A" (Federal Register 2026-22192). The same notice says HHS "may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises" and that the policy "is not binding on HHS or the public."

What that means for a buyer:

• Not approval. "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed" (Federal Register 2026-22192).
• Single peptides, specified forms. Superpower's summary of the policy says "Blends aren't covered" and "oral formulations need evidence of adequate absorption in humans" (Superpower peptides page). We could not read the HHS appendix that lists the covered forms (hhs.gov returned HTTP 403 to us on 30 October 2026), so that detail rests on program and press summaries.
• States still decide. The policy binds no state. Superpower states "BPC-157 is not available in all 50 states" (Superpower BPC-157 page).

Compounded drugs are not FDA-approved, and this policy is interim and can be withdrawn at any time; status checked on 30 October 2026. The full legal picture is in is BPC-157 legal and the HHS peptide policy explained.

How a BPC-157 prescription program works

Programs selling BPC-157 under the policy follow the usual telehealth pattern, with a few extra steps the policy requires:

1. Online assessment. You describe your goals, health history and medications.
2. Clinician review. A licensed clinician decides whether to prescribe. Superpower states its program "is intended for adults with a specific injury or musculoskeletal concern affecting pain, movement or everyday function" (Superpower BPC-157 page).
3. 503A pharmacy. A state-licensed pharmacy compounds a patient-specific prescription. Under the policy, each ingredient lot "needs a detailed certificate of analysis covering identity, potency, impurities and contaminants" (Superpower peptides page).
4. Monitoring. Superpower's protocol calls for "symptom check-ins every four weeks and CBC/CMP monitoring every six months while treatment continues" (Superpower peptides page).

The prescriber sets the form, amount and schedule. We do not publish doses. If you are weighing pills against injections, see oral BPC-157 vs injection, and for the wider process, how to get peptides prescribed online.

Programs that prescribe BPC-157

These are the programs in our tracker with a published BPC-157 price, read on the provider's own page on 30 October 2026. We add programs once they publish a price we can source.

Read the Superpower review for its scores, pros and cons, and the BPC-157 price table for the live figures. Other large telehealth brands have announced waitlists; we list them only once their own pages show a price.

Prescription BPC-157 versus research-use vials

BPC-157 has been sold online for years as a research-use-only product, without a prescription. FDA has said that label does not change what a product is: in a 2023 warning letter to an online seller of BPC-157, FDA wrote that "evidence obtained from your website establishes that your products are intended to be drugs for human use" (FDA warning letter, June 2023). The HHS policy does not cover those products at all. We do not list research-use sellers. The differences are set out in research vs prescription peptides and compounded peptide safety.

What to ask a program before you pay

• Which 503A pharmacy compounds the BPC-157, and can you see the certificate of analysis for the ingredient lot?
• Is the product BPC-157 alone, or a blend? Blends fall outside the HHS policy.
• Which labs are required, when, and are they in the price?
• What happens to your prepaid months if HHS withdraws the policy or your state blocks it?
• Who reviews your check-ins, and how do you report a reaction?
• What does the clinician say about the evidence for your specific problem, and what are the established alternatives?

FAQ

What is BPC-157 and how do you get a prescription?

BPC-157 is a synthetic 15-amino-acid peptide based on a protein in stomach juice, studied mostly in preclinical work for tissue repair. To get it legally, you complete an online assessment with a telehealth program, a licensed clinician decides whether to prescribe, and a state-licensed 503A pharmacy compounds it for you. Compounded BPC-157 is not FDA-approved, and the HHS policy allowing this is interim.

Can you get BPC-157 online?

Yes, through a licensed telehealth program that issues a prescription filled by a 503A pharmacy. As of 30 October 2026, the program in our tracker takes preorders with a target ship date in late November, pending pharmacy confirmation. Availability depends on your state. Products sold online as "research use only" without a prescription are not covered by the HHS policy.

Is BPC-157 FDA approved?

No. BPC-157 is not FDA-approved for any condition, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality. The October 2026 HHS policy only says HHS does not intend to take enforcement action against licensed pharmacies and physicians compounding it under conditions. HHS can revisit the policy at any time, for example if a safety signal appears.

How much does BPC-157 cost with a prescription?

Prescription BPC-157 starts at $149 a month at Superpower, which bundles a clinician review, a blood panel and membership. The first month is charged at preorder and refunded if a clinician does not approve you. Our BPC-157 cost guide covers what is included and the fine print.

Does BPC-157 work?

Evidence in people is too thin to say. Three small studies with 30 participants in total reported improvement, but a 2026 systematic review rated the certainty of that evidence very low. Most positive results come from preclinical research. Superpower's own page states that a healing benefit in humans has not been established. Ask your clinician about established treatments for your condition too.

Is the BPC 157 peptide from a pharmacy the same as a research vial?

Not in any way you can check. A compounded prescription comes from a state-licensed pharmacy that, under the HHS policy, must use an ingredient from an FDA-registered maker with a tested certificate of analysis. A research-use vial comes with no prescription, no clinician and no pharmacy oversight. FDA has treated such products as unapproved drugs.

Compare prescription BPC-157 programs on price, labs and oversight on our best peptide programs page, or see the live BPC-157 price table.